ElevateBio
ElevateBio is a biotechnology company focused on cell and gene therapy, providing R&D and manufacturing through its Life Edit and BaseCamp® platforms.
Secondary Market Price
Secondary Market Price
How ElevateBio Measures Up
To help you manage your ElevateBio equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of ElevateBio's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future ElevateBio Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for ElevateBio's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
ElevateBio is a technology-focused company that operates a portfolio of cell and gene therapy companies. It provides its portfolio companies with services including research, process development, cGMP manufacturing, and clinical development. The company's business is structured around two main components: Life Edit, which handles gene editing technologies and R&D, and BaseCamp®, which provides process development and cGMP manufacturing for genetic medicines like cell therapies, viral vectors, and mRNA. Founded in 2017, the company is headquartered in Waltham, Massachusetts, and has raised a total of $845 million in funding, including a $401 million Series D round in June 2023.
Looking forward, ElevateBio aims to expand its partnerships and use artificial intelligence to accelerate its gene editing and discovery work. The company recently appointed Christopher Murphy as its new Chief Executive Officer. In other recent developments, its BaseCamp® manufacturing facility received certification from the Initiative for Certification of Manufacturing Capabilities (ICMC™) for viral gene delivery, non-viral gene delivery, and cell therapy. ElevateBio is also supporting partners like Kyverna Therapeutics by manufacturing its autologous CAR-T cell therapy candidate for autoimmune diseases.
- AyurMaya Capital Management Fund
- Matrix Capital Management
- Woodline
- Lee Family Office (Asia)
- Novo Nordisk
- The Invus Group
- Emerson Collective
- SoftBank Vision Fund 2
- Fidelity Management & Research Company
- MPM Capital
- F2 Ventures
- Redmile Group
- EcoR1 Capital
- Samsara BioCapital
- Surveyor Capital (a Citadel company)
- EDBI
- Vertex Ventures
- iTochu
- A large institutional investor
- Co-Founder, David Hallal
- Co-Founder, Mitchell Finer
- Co-Founder, Vikas Sinha
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is ElevateBio worth joining?
Deciding whether to join a company like ElevateBio is a personal choice that depends on your career goals and the company's culture. If you receive an offer that includes equity, a platform like Prospect can help you understand and maximize the value of your compensation package.
What should I do with my ElevateBio stock?
The best strategy for your ElevateBio stock depends on your personal financial goals, tax situation, and risk tolerance. Tools like Prospect can help you create a customized plan by modeling different scenarios and providing tax-optimized exercise strategies.
Can you sell ElevateBio stock?
As a private company, ElevateBio stock is not traded on a public exchange, but you may be able to sell shares through company-approved tender offers or on secondary markets. Prospect offers tools to help you navigate these sales by determining how much to sell and which shares are the most tax-optimal to part with.
How can I find the value of my ElevateBio stock?
The official value of private stock is determined by a 409A valuation, but this doesn't always reflect its potential market worth. To get a better projection, you can use platforms like Prospect, which use predictive models trained on venture capital data to forecast your equity's value.
What is ElevateBio's equity worth?
The precise worth of ElevateBio's equity fluctuates and is formally set by its 409A valuation for tax purposes. For a forward-looking estimate of its potential, services like Prospect provide predictive models to help you understand the future value of your holdings.
What is ElevateBio's stock ticker symbol?
ElevateBio is a private company, so it does not have a stock ticker symbol and is not traded on public stock exchanges. Ticker symbols are only assigned to companies once they become publicly listed through an Initial Public Offering (IPO).
Can I buy or sell ElevateBio stock?
Selling stock in a private company like ElevateBio is typically restricted to specific events like tender offers, which platforms like Prospect can help you navigate. Buying shares is generally limited to accredited investors or employees participating in specific company programs.
What is the criteria to buy or invest in ElevateBio stock?
Investing in a private company like ElevateBio is typically reserved for accredited investors who meet specific income or net worth thresholds defined by financial regulators. Employees may also acquire stock through their equity compensation packages.
